Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Study Links Metabolic Syndrome, Inflammation to Cognitive Decline
18 November 2004. The metabolic syndrome—a constellation of cardiovascular and diabetes risk factors such as abdominal obesity, high blood pressure, and high triglycerides—is associated with an increased risk of cognitive decline, according to a report in the 10 November JAMA. Kristine Yaffe of the University of California, San Francisco, and her colleagues there and at other institutions also provide evidence suggesting that inflammation is an important factor in whether or not metabolic syndrome will cause cognitive decline.

Yaffe and colleagues followed elderly subjects (aged 70-79 years) in a longitudinal, prospective, observational study of aging and body composition. In order to better correlate results with the effects of the metabolic syndrome, the researchers excluded people with diabetes or very high elevations of blood pressure or triglycerides. Of the 2,632 subjects, 1,016 had metabolic syndrome (defined as three or more of the following: abdominal obesity, high blood pressure, high triglycerides, high fasting glucose, or low HDL cholesterol) at baseline. Compared with the remaining 1,616 subjects, those with metabolic syndrome were more likely to experience cognitive impairment over the next four years (26 percent vs. 21 percent, multivariate adjusted relative risk, 1.20; 95 percent CI, 1.02-1.41). Cognitive impairment was defined as a five-point or greater decline on a modified MMSE at follow-up in three or five years.

The researchers report a statistically significant interaction between inflammation (as indicated by increased serum IL6 and C-reactive protein) and metabolic syndrome in increasing the risk of cognitive decline (P = .03). When they stratified subjects into tertiles by their serum levels of these two proinflammatory markers, Yaffe and colleagues found that among subjects who were in the highest tertiles for both markers, the presence of metabolic syndrome was associated with an increased risk of cognitive impairment on follow-up (multivariate adjusted relative risk, 1.66; 95 percent CI, 1.19-2.32). Conversely, among subjects with the lowest tertiles of inflammatory markers, the presence of metabolic syndrome did not increase the likelihood of cognitive decline (multivariate adjusted relative risk, 1.08; 95 percent CI, 0.89-1.30).

How inflammation, metabolic syndrome, and cognitive impairment are related is unclear. For example, does metabolic syndrome lead to inflammation that can, in turn, impact cognition, or does inflammation promote metabolic syndrome? Or, does the cause/effect relationship run both ways? Much remains to be worked out about the interrelationship among metabolic syndrome, inflammation, and cognitive decline, according to the authors.—Hakon Heimer.

Reference:
Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004 Nov 10;292(18):2237-42. Abstract

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad